News

Exploring the Cutting Edge

"This is the best time I have seen to deploy capital into healthcare assets"

Hashan De Silva

Founder

MAY 14, 2024

Investor who bought Neuren at $1 a share lowers sights on $200m fund

Biotech investor Hashan De Silva is launching a new fund because he sees opportunities in medical and healthcare firms, thanks to market turmoil.

Read full post

MAY 13, 2024

Be greedy when others are fearful: Why now is the time to invest in healthcare

The KP Rx Healthcare Opportunities Fund is targeting Australia & New Zealand's most innovative healthcare companies. Find out how they do it

Read full post

MAY 2, 2024

This fundie invested in Neuren at a $70m valuation. It's now $2.4 billion.

The KP Rx Healthcare Opportunities Fund is targeting Australia & New Zealand's most innovative healthcare companies. Find out how they do it

Read full post

MAY 1, 2024

Backed by industry titans, leveraging Australia's healthcare innovation

Early-stage healthcare investment is not for the faint-hearted (or under-researched). No one could accuse Hashan De Silva of either.

Read full post

Mar 25, 2024

Neuren –
Where to from here?

There is much more to come from Neuren. Following two years of substantial progress, we see significant upside from current levels.

Read full post

Feb 13, 2024

Why analysts love these eight medtech stocks

The sector that straddles healthcare and tech has professionals searching for companies that could be tomorrow’s big winners after Pro Medicus.

Read full post

Feb 12, 2024

Bupa becomes a venture capital player

Bupa Asia Pacific has joined the list of corporates trying their hand at venture capital investing, raising a $20 million fund with the aim of backing early stage start-ups focused on healthcare.

Read full post

DEC 11, 2023

New fund targets companies battered by market doubts

A new venture capital fund aimed at funding cash-starved Australian medical, biotech and health technology start-ups has banked $40 million of a planned $200 million.

Read full post

Aug 23, 2023

Technology float CurveBeam AI
graduates to ASX

CurveBeam AI has convinced fund managers to back its ASX debut with the prospect of strong sales growth in the US healthcare market predicated on more accurate osteoarthritis diagnoses.

Read full post

Apr 12, 2023

Tiger cub hedge fund Karst Peak’s healthcare lead strikes out

There’s a new VC-style healthcare fund in town, as Hong Kong hedge fund Karst Peak Capital’s Sydney-based healthcare partner Hashan De Silva leaves to hang his own shingle.

Read full post

MAR 13, 2023

FDA drug approval lifts biotech Neuren to $1b valuation

Biotech Neuren Pharmaceuticals surged to a $1 billion valuation on Monday after the US healthcare regulator, approved its trofinetide drug for the treatment of neurological disorder Rett syndrome.

Read full post

Oct 11, 2022

Medical imaging company kicks off $15m pre-IPO

Brian Flannery-backed bone fragility imaging tech company CurveBeam AI is tapping investors for $15 million ahead of a 2023 float.

Read full post

Feb 28, 2022

A de-risked biotech with 4x upside

In 2020, we acquired a major stake in a biotech company developing orphan drugs to combat this severe neurological condition.

Read full post